Cognitive Research
PE-22-28 (Spadin)
BioHarmony verdict
Neutral
PE-22-28 is a synthetic spadin analogue that blocks the TREK-1 potassium channel, a target with a clean and well-characterized link to fast-acting antidepressant effects in rodents, per Mazella 2010 and Djillani 2017.
Read full reportWhat is PE-22-28 (Spadin)?
PE-22-28 is a lab-made peptide that blocks the TREK-1 potassium channel, and that single action is the whole pitch. TREK-1 quietly sets how excitable a neuron is, so blocking it raises the firing of serotonin neurons and, in animals, behaves like a fast-acting antidepressant. The target has a genuinely clean backstory: deleting the TREK-1 gene in mice makes them resistant to depression, which is what first put this channel on the map as a depression target, per Mazella 2010. PE-22-28 itself is a 7-amino-acid fragment engineered from spadin, a sortilin-derived peptide, and it was built to hit TREK-1 harder and last longer than its parent, per Djillani 2017.
From the BioHarmony report, reviewed 2026-09-08.
How it is thought to work
Blocks the TREK-1 background potassium channel, raising neuronal excitability and serotonergic firing
Safety watch-outs
- Palpitations, chest tightness, or blood-pressure swings: stop immediately, since TREK-1 is expressed in heart and vascular tissue and human…
- Unexplained low blood sugar or shakiness: stop, since TREK-1 blockade acts as an insulin secretagogue in animals.
- Worsening mood, agitation, or suicidal thinking: stop and seek help, since no human safety or dose-response data exists to guide use.
- Any sign of contamination, fever, or injection-site infection from grey-market material: stop and seek care.
Full risk profile in the BioHarmony report.
Dosing as published
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (1)
Attributed viewpoints, separate from primary research.
- PE-22-28 Peptide: Benefits, Dosage & Side EffectsJay Campbell · 2026-04-29
Trust & sourcing
PE-22-28 has published cell and mouse-model research on TREK-1 inhibition and antidepressant-like activity. The reviewed study does not establish human safety or effectiveness.
Primary sources
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant ActivityPubMed / Frontiers in Pharmacology · 2017-09-22
Related peptides for brain, mood & sleep
Free guide
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.